• Home
  • About MJResearchCo
    • What do we offer?
    • Why are we different?
    • Why are we doing this?
    • About Mike and Colin
  • Podcast & Videos
  • Contact Us
  • Log In
MJResearchCo
  • Extract Newsletter
  • Sector
  • Regional Insight
  • Comps & Markets
  • Companies
  • Subscribe
Select Page
Cannabis SPAC Analysis – November 2021

Cannabis SPAC Analysis – November 2021

by Mike and Colin | Nov 18, 2021 | Company Analysis, Data & Analysis, In the News, M&A / Capital Raise, Macro

On October 19, 2019, Mike Regan presented on SPACs (Special Purpose Acquisition Corps) at the MJBizCon Finance Forum. The presentation walked through: Key risks to investing in SPACs How to invest across the SPAC lifecycle process The players and incentives during the...
Weedmaps cuts guidance; Where will margins stabilize?

Weedmaps cuts guidance; Where will margins stabilize?

by Mike and Colin | Nov 16, 2021 | Company Analysis, Earnings Report

MAPS guided significantly below prior guidance for 4Q21 and 2022, blaming softness on a demand shift to the illicit market and slower than expected license issuances. Our more detailed review and updated model for Premium Members can be found below. While the...
Hydrofarm (HYFM) Cuts 4Q21 Guidance 50% & Buys IGE; 2022 at risk or sales delayed?

Hydrofarm (HYFM) Cuts 4Q21 Guidance 50% & Buys IGE; 2022 at risk or sales delayed?

by Mike and Colin | Oct 29, 2021 | Company Analysis, Earnings Report

Hydrofarm (HYFM), a NASDAQ traded supplier and distributor of hydroponics products with high exposure to the legal cannabis industry, guided 3Q21 and 2021 sales down on Octboer 26 as they increased their credit line to $125 million and acquired Innovative Growers...
UPDATED Canopy-Wana & Cronos-Pharmacann Options: Smart for Sellers, what do Canadian LPs get?

UPDATED Canopy-Wana & Cronos-Pharmacann Options: Smart for Sellers, what do Canadian LPs get?

by Mike and Colin | Oct 15, 2021 | Company Analysis, M&A / Capital Raise, Macro

Canopy is paying $297.5M for the right to buy Wana Brands when it “Federally permissible”, and Cronos paid $110.4 million for the right to buy 10.5% of Pharmacann when legal. What exactly are they getting, why are they buying, and why is it smart for Wana and...
Weedmaps cuts guidance; Where will margins stabilize?

Weedmaps, Q2 Review & Updated Model

by Mike and Colin | Aug 13, 2021 | Company Analysis, Earnings Report

Premium members can read our analysis on the Q2 2021 results from WM Technology, formerly known as Weedmaps. This article also includes an updated working model with capital structure, valuation, client counts, and more. This article is for subscribers only. Please...
« Older Entries
  • Terms of Use
  • Privacy Policy
  • Copyright © MJResearchCo
  • Twitter
  • RSS
Website Designed by: AeroWeb - Boston Web Design & Hosting